Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items grows, but more slowly than its trailing trend
Q1 FY2026 other non-cash items of $2.08M (cash outflow) rose 39.8% year over year, behind the +231.1% change in trailing-twelve-month other non-cash items.
What to watch
Whether quarterly growth recovers from +39.8% toward the trailing-twelve-month pace of +231.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (4.65M) USD
- Year-over-year change
- -2602.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.65M) | -2602.0% |
| FY2024 | 2024-12-31 | (171.92K) | — |
Other Non-Cash Items vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 other non-cash items of $5.1M is the 9th largest of the 10 companies compared; the peer median is $8.44M.
- Its year-over-year change of +231.1% is the 3rd highest of 5, against a peer median of +1219.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.32M | — | — | — | |
| FY2025 | $9.59M | +2211.0% | +26.2% | — | |
| LTM Mar 2026 | $9.34M | +227.7% | — | — | |
TACOUBerto Acquisition Corp. Unit | FY2025 | $8.44M | — | — | — |
| FY2025 | $8.44M | — | — | — | |
| LTM Mar 2026 | $7.9M | — | — | — | |
| FY2025 | $7.38M | +3906801.6% | — | — | |
OYSEOyster Enterprises II Acquisition Corp | FY2025 | $6.22M | — | — | — |
| LTM Mar 2026 | $5.1M | +231.1% | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $2.96M | -1458895.0% | — | — |
| Peer median (excluding DMAA) | $8.44M | +1219.4% | +26.2% | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (479) | 3.97M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 132 | 138.85K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | 144.9K |
| Other Working Capital | 132 | (6.05K) |
| Other Non-Cash Items | (171.92K) | (4.65M) |
| Operating Cash Flow | (295) | (539.19K) |
| Capital Expenditures | 5 | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | 0 | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | (231.15M) |
| Investing Cash Flow | 0 | (231.15M) |
| Debt Repayment | 502.21K | (900K) |
| Common Stock Issued | (328.6K) | 232.05M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 1 | 543.97K |
| Financing Cash Flow | 173.62K | 231.69M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.35K | 4.79K |
| Free Cash Flow | (295) | (539.19K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.